A Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome;
A Prospective, Phase-II Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Richter's Syndrome. GIVeRS Protocol: On Behalf of the Israeli CLL Study Group
Sponsor: Bnai Zion Medical Center
A PHASE2 clinical study on Richter's Syndrome, this trial is completed. The trial is conducted by Bnai Zion Medical Center and has accumulated 9 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Jan 2025 — Sep 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Dec 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE2
Status: Unknown → Active Not Recruiting
-
Oct 2024 — Dec 2024 [monthly]
Unknown PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jan 2022 — Jul 2024 [monthly]
Recruiting PHASE2
-
Oct 2021 — Jan 2022 [monthly]
Recruiting PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE2
First recorded
Aug 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bnai Zion Medical Center
- Tel-Aviv Sourasky Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .